ArticleArchives of medical science : AMS2022

Which patients at risk of cardiovascular disease might benefit the most from inclisiran? Polish experts' opinion. The compromise between EBM and possibilities in healthcare.

Maciej Banach et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.